PDE4 inhibitors: New xanthine analogues

Bioorganic and Medicinal Chemistry Letters

Volumn 8, Issue 20, 1998, Pages 2925-2930

  Montana, John G ^a   Cooper, Nicola ^a   Dyke, Hazel J ^a   Gowers, Lewis ^a   Gregory, Joanna P ^a   Hellewell, Paul G ^b   Miotla, Jadwiga ^b   Morris, Ken ^d   Naylor, Robert ^c   Tuladhar, Bishwa ^c   Warneck, Julie B H ^a  

^a Chiroscience Ltd   (United Kingdom)

^b NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^c UNIVERSITY OF BRADFORD   (United Kingdom)

^d Maybridge Chemical Company Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE IV INHIBITOR; THEOPHYLLINE; XANTHINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; ENZYME INHIBITION; EOSINOPHILIA; FERRET; GUINEA PIG; NONHUMAN; ORAL DRUG ADMINISTRATION; SKIN; VOMITING;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; ANIMALS; EOSINOPHILIA; FERRETS; GUINEA PIGS; PHOSPHODIESTERASE INHIBITORS; SKIN DISEASES; THEOPHYLLINE; VOMITING; XANTHINES;

EID: 0032552846     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(98)00524-1     Document Type: Article

References (23)

1. 1. Giembycz, M. A. Trends Pharmacol. Sci. 1996, 17, 331-336.
2. 2. Nicholson, C.D.; Shahid, M. Pulmon. Pharmacol. 1994, 7, 1; Palacios, J.M.; Beleta, J.; Segarra, V. Il Farmaco 1995, 50, 819.
3. 2. Nicholson, C.D.; Shahid, M. Pulmon. Pharmacol. 1994, 7, 1; Palacios, J.M.; Beleta, J.; Segarra, V. Il Farmaco 1995, 50, 819.
4. 3. Demoliou-Mason, C.D. Exp. Opin. Ther. Patents 1995, 5, 417.
5. 4. Teixeira, M.M.; Gristwood, R.W.; Cooper, N.; Hellewell, P.G. TIPS 1997, 18, 164; Banner, K.H.; Page, C.P. Clin. Exp. Allergy 1996, 26(Supplement 2), 2.
6. 4. Teixeira, M.M.; Gristwood, R.W.; Cooper, N.; Hellewell, P.G. TIPS 1997, 18, 164; Banner, K.H.; Page, C.P. Clin. Exp. Allergy 1996, 26(Supplement 2), 2.
7. 5. Perasson, C.G.A.; Andersson, K.E.; Kjellin, G. Life Sci. 1986, 38, 1057
8. 6. Sakai, R.; Konno, K.; Yamamoto, Y.; Sanae, F.; Takagi, K.; Hasegawa, T.; Iwasaki, N.; Kakiuchi, M.; Kato, H.; Miyamoto, K. J. Med. Chem. 1992, 35, 4039; Miyamoto, K.; Yamamoto, Y.; Kurita, M.; Sakai, R.; Konno, K.; Sanae, F.; Ohshima, T.; Takagi, K.; Hasegawa, T.; Iwasaki, N.; Kakiuchi, M.; Kato, H. J. Med. Chem. 1993, 36, 1380; Buckle, R.; Arch, J.; Connolly, B.; Foster, K.; Murray, K.; Readshaw, S.; Smallridge, M.; Smith, D. J. Med. Chem. 1994, 37, 476.
9. 6. Sakai, R.; Konno, K.; Yamamoto, Y.; Sanae, F.; Takagi, K.; Hasegawa, T.; Iwasaki, N.; Kakiuchi, M.; Kato, H.; Miyamoto, K. J. Med. Chem. 1992, 35, 4039; Miyamoto, K.; Yamamoto, Y.; Kurita, M.; Sakai, R.; Konno, K.; Sanae, F.; Ohshima, T.; Takagi, K.; Hasegawa, T.; Iwasaki, N.; Kakiuchi, M.; Kato, H. J. Med. Chem. 1993, 36, 1380; Buckle, R.; Arch, J.; Connolly, B.; Foster, K.; Murray, K.; Readshaw, S.; Smallridge, M.; Smith, D. J. Med. Chem. 1994, 37, 476.
10. 6. Sakai, R.; Konno, K.; Yamamoto, Y.; Sanae, F.; Takagi, K.; Hasegawa, T.; Iwasaki, N.; Kakiuchi, M.; Kato, H.; Miyamoto, K. J. Med. Chem. 1992, 35, 4039; Miyamoto, K.; Yamamoto, Y.; Kurita, M.; Sakai, R.; Konno, K.; Sanae, F.; Ohshima, T.; Takagi, K.; Hasegawa, T.; Iwasaki, N.; Kakiuchi, M.; Kato, H. J. Med. Chem. 1993, 36, 1380; Buckle, R.; Arch, J.; Connolly, B.; Foster, K.; Murray, K.; Readshaw, S.; Smallridge, M.; Smith, D. J. Med. Chem. 1994, 37, 476.
11. 7. Muller, T.; Engels, P.; Fozard, J.R. Trends Pharmacol. Sci. 1996, 17, 294; Kelly, J.J.; Barnes, P.J.; Giembycz, M.A. Biochem. 1996, 318, 425; Jacobitz, S.; McLaughlin, M.M.; Livi, G.P.; Burman, M.; Torphy, T.J. Mol. Pharmacol. 1996, 50, 891.
12. 7. Muller, T.; Engels, P.; Fozard, J.R. Trends Pharmacol. Sci. 1996, 17, 294; Kelly, J.J.; Barnes, P.J.; Giembycz, M.A. Biochem. 1996, 318, 425; Jacobitz, S.; McLaughlin, M.M.; Livi, G.P.; Burman, M.; Torphy, T.J. Mol. Pharmacol. 1996, 50, 891.
13. 7. Muller, T.; Engels, P.; Fozard, J.R. Trends Pharmacol. Sci. 1996, 17, 294; Kelly, J.J.; Barnes, P.J.; Giembycz, M.A. Biochem. 1996, 318, 425; Jacobitz, S.; McLaughlin, M.M.; Livi, G.P.; Burman, M.; Torphy, T.J. Mol. Pharmacol. 1996, 50, 891.
14. 8. Duplantier, A.J.; Biggers, M.S.; Chambers, R.J.; Cheng, J.B.; Cooper, K.; Damon, D.B.; Eggler, J.F.; Kraus, K.G.; Marfat, A.; Masamune, H,; Pillar, J.S.; Shirley, J.T.; Umland, J.P.; Watson, J.W. J. Med. Chem. 1996, 39, 120.
15. 9a. Papesch, V. and Schroder, E.F. J. Org. Chem. 1951, 16, 1879.
16. 9b. Ohtsuka, Y. Bull. Chem. Soc. Jap. 1973, 46, 506.
17. 9c. Bredereck, H. and Edenhofer, A. Chem. Berichte 1955, 1306.
18. 10. Teixeira, M.M.; Reynia, S.; Robinson, M.; Shock, A.; Williams, T.J.; Williams, F.M.; Rossi, A.G.; Hellewell, P.G. Br. J. Pharmacol. 1994, 111, 811; Teixeira, M.M.; Williams, T.J.; Hellewell, P.G.; Br. J. Pharmacol. 1993, 110, 416.
19. 10. Teixeira, M.M.; Reynia, S.; Robinson, M.; Shock, A.; Williams, T.J.; Williams, F.M.; Rossi, A.G.; Hellewell, P.G. Br. J. Pharmacol. 1994, 111, 811; Teixeira, M.M.; Williams, T.J.; Hellewell, P.G.; Br. J. Pharmacol. 1993, 110, 416.
20. 11. Kallos, P. and Kallos, L. Int. Arch. Appl. Immunol. 1984, 73, 77; Sanjar, S. Aoki, S. Kristersson, A. Smith, D. and Morley, J.; Br J Pharmacol. 1990, 99, 679.
21. 11. Kallos, P. and Kallos, L. Int. Arch. Appl. Immunol. 1984, 73, 77; Sanjar, S. Aoki, S. Kristersson, A. Smith, D. and Morley, J.; Br J Pharmacol. 1990, 99, 679.
22. 12. Costall, B.; Domeney, A. M.; Naylor, R. J; Tattersall, F. D. Neuropharmacology 1987, 26, 1321-1326.
23. 13. The mediators used as inflammagens in the guinea pig skin eosinophilia model were platelet aggregating factor (PAF), Arachidonic acid (AA) and zymosan-activated plasma (ZAP). Additionally sensitisation to bovine gamma globulin followed by an id challenge of antisera results in a passive cutaneous anaphylactic (PCA) response.